Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$57.98+2.25%
Close 2026-07-07 · 1-day change
Reading BMY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BMY free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading BMY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BMY free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Bristol Myers Squibb's AI overhaul and oncology trials have to keep compounding to justify the price. Revenue grew 3% year over year, and the last quarter beat expectations by 37%. It trades at 9.6× P/E versus a peer median of 26×, indicating that the price reflects less growth than forecasted. If BMY cuts guidance on the next call, that's a meaningful negative, as the Street tends to walk down estimates and the stock usually takes a leg lower. Peer multiples imply a price about 11% above where it trades. This read is provisional.
Trailing returns as of 2026-07-07. BMY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering BMY (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A consensus fair price across 13 valuation methods, at three horizons. Current price $57.98. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
AI overhaul and oncology trials enhance growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Partnership with Anthropic supports innovation and growth.
Building next growth cycle aligns with financial guidance.
Collaboration in China opens new drug development avenues.
